My Treatment Approach: Optimizing Treatment for Chronic GVHD - Episode 6
Overview of the ROCKstar Study
Medical experts discuss the data that led to belumosudil’s FDA approval.
Video Player is loading.
Video content above is prompted by the following:
- Dr Holtan:Please review data that led to belumosudil’s FDA approval (Jagasia M, et al. J Clin Oncol. 2021; Cutler C, et al. Blood. 2021).
- Study design and patient demographics
- Efficacy data (duration of effect, need for additional treatments, data on decrease in formation of scar tissue and decrease in immune cell activity, etc).
- Safety profile of belumosudil and adverse effect management.
Related Content:
